MAP2K7 and pancreatic neoplasm: Activation of the MEK/ERK signaling pathway by the oncogenic KRAS G12D mutation increases secretion of IL-10 and TGF-β from pancreatic cancer cells, which promotes conversion of T-cells to an immunosuppressive regulatory T-cell (Treg) state (87).